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Edited by Jesus AvilaAbstract Intraneuronal inclusions made of hyperphosphoryl-
ated microtubule-associated protein tau are a deﬁning neuro-
pathological characteristic of Alzheimer’s disease, and of
several other neurodegenerative disorders. Many phosphoryla-
tion sites in tau are S/TP sites that ﬂank the microtubule-binding
repeats. Others are KXGS motifs in the repeats. One site up-
stream of the repeats lies in a consensus sequence for AGC
kinases. This site (S214) is believed to play an important role
in the events leading from normal, soluble to ﬁlamentous, insol-
uble tau. Here, we show that all AGC kinases tested phosphor-
ylated S214. RSK1 and p70 S6 kinase also phosphorylated the
neighbouring T212, a TP site that conforms weakly to the
AGC kinase consensus sequence. MSK1 phosphorylated S214,
as well as S262, a KXGS site in the ﬁrst repeat, and S305 in
the second repeat.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Many neurodegenerative diseases are characterized by the
presence of abnormal ﬁlamentous protein inclusions in the
brain. In Alzheimer’s disease (AD), these inclusions are made
of hyperphosphorylated tau protein. Together with the extra-
cellular b-amyloid deposits, they constitute the deﬁning neuro-
pathological characteristics of AD [1]. Inclusions made of
hyperphosphorylated tau, in the absence of extracellular
deposits, are characteristic of progressive supranuclear palsy,
corticobasal degeneration, Pick’s disease, argyrophilic grain
disease and frontotemporal dementia and parkinsonism linked
to chromosome 17 (FTDP-17) [1,2]. The identiﬁcation of over
40 diﬀerent mutations in Tau in FTDP-17 has ﬁrmly estab-
lished that dysfunction of tau protein is central to the neurode-
generative process [1,3–5].
In adult human brain, six tau isoforms are produced from a
single gene by alternative mRNA splicing [6–9]. They diﬀer by
having three or four conserved repeats, located in tandem in*Corresponding author. Fax: +44 1223 402197.
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doi:10.1016/j.febslet.2007.05.009the C-terminal region, and no, one or two inserts in the N-ter-
minal portion. The repeats constitute the microtubule-binding
domains of tau. Tau binds to tubulin through these repeats
and promotes microtubule assembly [10,11]. In developing
brain, only the shortest isoform (three repeats and no amino-
terminal inserts) is expressed [8,12]. Phosphorylation of tau
is developmentally regulated, in that tau from developing brain
is phosphorylated more than tau from adult brain [13–16]. The
ability of tau to bind to and stabilise microtubules correlates
inversely with its phosphorylation [17], which may in turn
facilitate self-assembly. Protein chemical and immunochemical
studies have identiﬁed more than 25 phosphorylation sites in
ﬁlamentous tau, about half of which are serine and threonine
residues followed by proline [18–20]. Consequently, glycogen
synthase kinase-3 (GSK3) [21,22], cyclin-dependent kinase 5
(cdk5) [23,24], mitogen-activated protein (MAP) kinase
[25,26] and stress-activated protein (SAP) kinases [27,28] have
been shown to phosphorylate tau protein at sites that are
hyperphosphorylated in the human tauopathies. Phosphoryla-
tion at many of these sites occurs in a signiﬁcant fraction of
fetal tau and a small fraction of tau from adult human brain.
However, some sites are phosphorylated in ﬁlamentous tau,
but not in tau from normal adult human brain.
Phosphorylation at S422 is such an example [29]. This SP
site can be phosphorylated by MAP kinase and SAP kinases
in vitro [28,29]. Triple phosphorylation of T212, S214 and
T217, as detected by the phosphorylation-dependent anti-tau
antibody AT100, is another example [30]. T212 and T217 are
TP sites, whereas S214 is located within a consensus sequence
[RXRXXS/T] for phosphorylation by members of the
AGC [PKA (cAMP-dependent protein kinase)/protein kinase
G/PKC (protein kinase C)] subfamily of protein kinases. It
comprises more than 50 diﬀerent members and includes en-
zymes involved in diverse aspects of cellular regulation [31].
In a transgenic mouse model of human tauopathy, AT100 rec-
ognizes only ﬁlamentous tau [32], suggesting that phosphoryla-
tion of T212, S214 and T217 plays an important role in tau
assembly.
Here, we report on the phosphorylation of recombinant
human tau protein by AGC kinases protein kinase B-alpha
(PKBa), serum- and glucocorticoid-induced kinase-1
(SGK1), p70 S6 kinase (S6K), p90 ribosomal S6 kinases 1
and -2 (RSK1 and RSK2) and mitogen- and stress-activated
protein kinase-1 (MSK1). All six kinases phosphorylated
S214, with RSK1 and p70S6 kinase also phosphorylating
T212. MSK1 phosphorylated S214, as well as S262 and S305
in the microtubule-binding repeat region of tau.blished by Elsevier B.V. All rights reserved.
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Fig. 1. Phosphorylation of recombinant tau by AGC kinases. (A)
Recombinant human tau (412 amino acid isoform) was incubated in
the presence of SGK1, p70S6 kinase, RSK1, RSK2, PKB, MSK1,
GSK3b and CaMKII. Tau incubated in the absence of kinase served as
the control. The reactions were separated on SDS–PAGE and the 32P
label incorporated into tau visualized by phosphorimaging ( 32P) of
dried gels stained with Coomassie Brilliant Blue (CBB). Molecular
weight markers (in kDa) are indicated on the left. (B) Immunoblot
analysis of recombinant tau phosphorylated by the above kinases.
Antibodies speciﬁc for the phosphorylation of tau at T212 (pT212),
S214 (pS214), T212, S214 and T217 (AT100), S262 and/or S356 (12E8)
were used. BR134 recognizes tau in a phosphorylation-independent
manner. Sarkosyl-insoluble tau from the brain of mice transgenic for
human P301S tau served as a positive control.
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2.1. Protein kinases
Active His-p70S6 kinase(1–421)T412E, SGK1(D1–59)S422D, His-
PKBa(D1–117)S473E, His-RSK1, His-RSK2, His-MSK1, His-GSK3b
and calcium/calmodulin-dependent protein kinase II (CaMKII) were
purchased from Upstate Biotechnology. For p70 S6 kinase, SGK1,
PKBa and MSK1, one unit of activity was that amount of enzyme
which incorporated 1 nmol phosphate into 1 nmol CROSStide sub-
strate peptide (GRPRTSSFAEG) in 1 min. For RSK1 and RSK2, 1
unit of activity was that amount of enzyme which incorporated 1 nmol
phosphate into 1 nmol long S6 substrate peptide (KEAKEKRQE-
QIAKRRRLSSLRASTSKSGGSQK) in 1 min. GSK3b was assayed
by the phosphorylation of the phospho-glycogen synthase peptide
YRRAAVPPSPSLSRHSSPHQSpEDEEE. One unit of activity was
that amount of enzyme which incorporated 1 nmol phosphate into
the phosphopeptide in 1 min. For CaMKII puriﬁed from rat forebrain,
one unit of activity was that amount of enzyme which incorporated
1 nmol phosphate into the synthetic peptide KKALRRQETVDAL
in 1 min.
2.2. Tau constructs
The 412 amino acid isoform of human brain tau was expressed in
E. coli from cDNA clone htau46 and expressed as described [33].
Site-directed mutagenesis (QuikChange, Stratagene) was used to gener-
ate the following 10 tau mutants (using the nomenclature of the 441
amino acid brain tau isoform): T212A; S214A; T212A/S214A;
S262A; S262A/S356A; S262A/S293A/S356A; S262A/S293A/S324A/
S356A; S262A/S293A/S305A/S324A/S356A; T212A/S262A/S293A/
S305A/S324A/S356A and T212A/S214A/S262A/S293A/S305A/S324A/
S356A. All constructs were veriﬁed by DNA sequencing.
2.3. Antibodies
The phosphorylation-independent anti-tau antibodies BR134 and
BR135 [6] were used. Antibodies pT212 and pS214 were purchased
from BioSource International (Camarillo, CA, USA). Antibody
AT100 [34] was purchased from Innogenetics (Ghent, Belgium). Anti-
body 12E8 [35] was a kind gift from Dr. P. Seubert (Elan Pharmaceu-
ticals, San Francisco, CA, USA). Immunoblot analysis was performed
as described [36], using 50 ng of protein per lane.
2.4. Phosphorylation assays
Phosphorylation assays (0.030 ml) were carried out at room temper-
ature and comprised 30 mM HEPES, 10 mM magnesium chloride,
100 lM [c-32P] ATP (approximately 106 cpm/nmol), 1 mM dithiothre-
itol, 10 mM b-glycerophosphate, tau protein (5 lg) and 1 U/ml p70 S6
kinase, SGK1, PKBa, RSK1, RSK2, MSK1 or CaMKII. When CaM-
KII was used, 40 lg/ml calmodulin and 1 mM CaCl2 were added.
Reactions were initiated by the addition of protein kinase and allowed
to proceed for 6 h. In some experiments, two protein kinases were used
in combination or added sequentially; in the latter case, the second en-
zyme was added 3 h after the ﬁrst and the reaction allowed to proceed
for a further 3 h. Phosphorylation was examined by SDS–PAGE and
autoradiography. The radioactive bands were quantitated using the
Typhoon Phosphorimager and analyzed with iQMac2.1 software
(Molecular Dynamics, Sunnyvale, CA, USA). Alternatively, incorpo-
ration of 32P-radioactivity was measured after adsorption to Whatman
P81 paper [26]. Sarkosyl-insoluble tau was extracted from the brains of
5-month-old mice transgenic for human P301S tau protein, as de-
scribed [32].3. Results
The relative levels of phosphorylation of wild-type recombi-
nant tau (412 amino acid isoform of human tau) by 1 U/ml
SGK1, p70S6K, RSK1, RSK2, PKB, MSK1, GSK3b and
CaMKII were assessed using the incorporation of 32P
(Fig. 1A). Preliminary experiments showed that the incorpora-
tion of 32P into tau had reached a plateau by 6 h. The phos-
phorylation reactions were therefore incubated for 6 h.
Incubation of diﬀerent amounts of recombinant tau with aconstant amount of protein kinase showed that incorporation
of 32P reached a plateau at approximately 5 lg of tau. Of the
AGC kinases tested, MSK1 and SGK1 gave the most robust
phosphorylation of recombinant tau. Tau protein incubated
with 1 U/ml MSK1 for 6 h incorporated 2.21 ± 0.14 mol phos-
phate per mol tau (n = 3). This ﬁgure was 1.30 ± 0.30 for tau
phosphorylated by SGK1. Phosphorylation by MSK1 also re-
sulted in a reduced mobility of recombinant tau on SDS–
PAGE. The AGC kinases p70S6K, RSK1, RSK2 and PKB
phosphorylated tau less well. Thus, tau protein incubated with
1 U/ml p70 S6 kinase for 6 h only incorporated
0.13 ± 0.04 mol phosphate per mol tau (n = 3). Phosphoryla-
tion of tau by CaMKII resulted in strong incorporation of
32P, with lower levels of incorporation following phosphoryla-
tion by GSK3b.
To identify sites in tau phosphorylated by AGC kinases,
phosphorylation-dependent antibodies speciﬁc for pT212,
pS214 and pS262/S356 (antibody 12E8) were used (Fig. 1B).
The kinases p70S6K and RSK1 generated reactivity with
125
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and CaMKII failed to generate reactivity with antibody
pT212. With antibody pS214, kinases SGK1, p70S6K,
RSK1, RSK2, CaMKII and, in particular, MSK1 generated
strong reactivity, whereas phosphorylation by PKB gave lower
levels of immunoreactivity. Phosphorylation of S262 and/or
S356 was assessed using antibody 12E8. Of the kinases tested,
only MSK1 and CaMKII generated 12E8-reactivity. None of
the enzymes tested generated AT100 reactivity when used
alone or in combination with PKA, even in the presence of
50 lg/ml heparin. The same was true when SGK1 was used
in combination with DYRK1A, JNK1, p70S6 kinase,
SAPK4/p38c or GSK3b (not shown). Sarkosyl-insoluble tau
from the brains of 5 month-old mice transgenic for human
P301S tau served as a positive control for the phosphospeciﬁc
anti-tau antibodies.
To corroborate these ﬁndings, tau proteins with mutations
T212A, S214A and T212A/S214A were phosphorylated by
SGK1, p70S6K, MSK1, RSK1 or RSK2 and incorporation
of 32P measured (Fig. 2). SGK1 phosphorylated T212A
strongly, with only residual phosphorylation of S214A and
T212A/S214A tau (15% and 10% of 32P incorporation, respec-
tively, with the value for wild-type tau taken as 100%). By con-
trast, p70S6 kinase phosphorylated T212A and S214A tau
proteins equally well. Incorporation of 32P into T212A/
S214A tau was 30% of that for the wild-type protein. MSK1
strongly phosphorylated T212A/S214A tau, with only a 25%
reduction in 32P incorporation compared to wild-type. Phos-w
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Fig. 2. Phosphorylation of wild-type and mutant tau by SGK1, p70 S6
kinase, MSK1, RSK1 and RSK2. Recombinant wild-type and mutant
tau was incubated in the presence of SGK1, p70 S6 kinase, MSK1,
RSK1 and RSK2. Tau incubated in the absence of kinase served as the
control. The reactions were separated on SDS–PAGE and the 32P label
incorporated into tau visualized by phosphorimaging (32P). Tau was
mutated at residues T212 and/or S214.phorylation of T212A tau by RSK1 resulted in a 30% reduc-
tion in 32P incorporation, with no signiﬁcant reduction
following phosphorylation by RSK2. Phosphorylation of
S214A tau by RSK1 resulted in a 50% reduction in the incor-
poration of 32P, with a 75% reduction following phosphoryla-
tion by RSK2.
Incorporation of 32P into T212A/S214A tau was greatest
when MSK1 was used, consistent with it phosphorylating a
number of additional sites in tau. The generation of 12E8-
immunoreactivity upon phosphorylation of htau46 by MSK1
indicated phosphorylation of S262 and/or S356, two of four
KXGS sites. We therefore mutated the KXGS sites (S262,
S293, S324, and S356), as well as S305, which was previously
shown to be phosphorylated by MARK/PAR1, a protein ki-
nase known to phosphorylate KXGS sites in tau [37]. Muta-
tion of these ﬁve sites from serine to alanine resulted in a
60% reduction in the incorporation of 32P into tau following
phosphorylation by MSK1 (Fig. 3). Additional mutagenesis
at T212 gave a similar reduction in incorporation. However,
when S214 was also mutated to alanine, a greater than 90%
reduction in the incorporation of 32P was observed. These ﬁnd-
ings show that S214, S262 and S305 are major sites in tau
phosphorylated by MSK1.32
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Fig. 3. Phosphorylation of wild-type and mutant tau by MSK1.
Recombinant wild-type and mutant tau was incubated in the presence
of MSK1. The reactions were separated on SDS–PAGE and the 32P
label incorporated into tau visualized by phosphorimaging. The results
were expressed as % of 32P label of wild-type tau (taken as 100%). Tau
was mutated at T212, S214 and S305, as well as at KXGS sites S262,
S293, S324 and S356 in the repeat region. The results are expressed as
the means ± S.E.M. (n = 3).
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AGC kinases preferentially phosphorylate serine and threo-
nine residues that lie in RXRXXS/T motifs [31]. They are acti-
vated by a variety of diﬀerent mechanisms. For example,
agonists that stimulate adenylate cyclase activity induce the
activation of protein kinase A (PKA), whereas those that stim-
ulate phosphoinositide 3-kinase (PI3K) activate PKB, p70S6
kinase and SGK. RSK isoforms are activated by the mito-
gen-activated protein (MAP) kinase family members ERK1
and ERK2, whereas MSK isoforms are activated by ERK1/
ERK2 and the stress- and cytokine-activated p38 MAP kinase.
In this paper, we show that PKB, SGK1, p70S6 kinase,
RSK1, RSK2 and MSK1 phosphorylate tau protein at S214,
in keeping with the consensus sequence RSRTPS (residues
209–214). These ﬁndings conﬁrm previous work showing that
PKB, SGK and p70S6 kinase phosphorylate tau at S214 [38–
41]. They show in addition that RSK1, RSK2 and MSK1
phosphorylate S214. RSKs and MSKs are ubiquitously ex-
pressed, with many cell types expressing several members of
each family [42]. Loss-of-function mutations in RSK2 cause
the Coﬃn-Lowry syndrome, a syndromic form of mental
retardation that shows X-linked inheritance [43]. Phosphoryla-
tion of S214 is known to reduce the ability of tau to interact
with microtubules [44,45]. Of the kinases tested, p70S6 kinase
and RSK1 also phosphorylated T212 in tau, a site that con-
forms weakly to the AGC kinase consensus site, with Arg res-
idues at positions -3 and -1. This site was strongly
phosphorylated by DYRK1A (not shown) and more weakly
by GSK3b, in keeping with previous ﬁndings [46,47]. None
of the protein kinases used generated the AT100 epitope, indi-
cating that individual tau molecules were not phosphorylated
simultaneously at T212, S214 and T217. Sequential phosphor-
ylation of tau by PKA and SAPK4/p38d or JNK2 in vitro gen-
erates the AT100 epitope [30].
Of the protein kinases known to phosphorylate S214, PKA
and CaMKII also phosphorylate the KXGS motifs in the re-
peat domain of tau (S262, S293, S324 and S356), consistent
with the consensus sequence K/RXXS [44,48,49]. These sites
are also phosphorylated by MAP/MT aﬃnity regulating ki-
nase (MARK), which does not phosphorylate S214 in tau
[37]. Phosphorylation of KXGS motifs strongly reduces the
interaction between tau and microtubules [50,51] and may con-
stitute an early event in the development of tauopathies [52]. It
has previously been reported that p70S6 kinase phosphorylates
tau at both S214 and S262 [40]. However, in the present study,
we failed to observe phosphorylation of S262. This diﬀerence
may be explained by the addition of heparin to the phosphor-
ylation reaction in the previous study.
When using T212A/S214A tau, we still observed robust
phosphorylation by MSK1, indicating the presence of addi-
tional sites. By using more extensive site-directed mutagenesis,
these were identiﬁed as S262 and S305 in the repeat region of
tau. S262 is in a KIGS site, whereas S305 (in the sequence
PGGGS) has previously been shown to be phosphorylated
by PKA and MARK [37]. The latter is activated by LKB1 ki-
nase [53]. These ﬁndings indicate that MSK1 phosphorylates
tau at sites typical of both AGC kinases and LKB1-activated
kinases. MSK isoforms are activated in vivo by MAP kinases
ERK1/ERK2 and SAP kinase p38 [54], enzymes that phos-
phorylate tau at the S/T-P sites that are hyperphosphorylated
in ﬁlamentous tau [25–28]. Together with the present results, ittherefore appears that the activation of MAP kinase family
members can lead to the phosphorylation of tau at most of
the sites that are hyperphosphorylated in the human tauopa-
thies.Acknowledgement: This work was supported by the U.K. Alzheimer’s
Research Trust and the Medical Research Council.References
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